The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… 
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…-
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… 
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…